Mirae Asset Global Investments Co. Ltd. Has $799,000 Stake in Sage Therapeutics, Inc. (NASDAQ:SAGE)

Mirae Asset Global Investments Co. Ltd. trimmed its position in Sage Therapeutics, Inc. (NASDAQ:SAGE) by 6.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 36,875 shares of the biopharmaceutical company’s stock after selling 2,708 shares during the quarter. Mirae Asset Global Investments Co. Ltd. owned 0.06% of Sage Therapeutics worth $799,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the stock. Wellington Management Group LLP raised its stake in Sage Therapeutics by 3.3% during the third quarter. Wellington Management Group LLP now owns 6,572,260 shares of the biopharmaceutical company’s stock worth $135,257,000 after acquiring an additional 208,630 shares in the last quarter. Vanguard Group Inc. raised its stake in Sage Therapeutics by 3.5% during the third quarter. Vanguard Group Inc. now owns 5,208,002 shares of the biopharmaceutical company’s stock worth $107,181,000 after acquiring an additional 175,565 shares in the last quarter. RTW Investments LP acquired a new position in Sage Therapeutics during the third quarter worth $105,976,000. Palo Alto Investors LP raised its stake in Sage Therapeutics by 17.0% during the third quarter. Palo Alto Investors LP now owns 1,005,776 shares of the biopharmaceutical company’s stock worth $20,699,000 after acquiring an additional 146,259 shares in the last quarter. Finally, Rafferty Asset Management LLC increased its stake in shares of Sage Therapeutics by 197.1% in the third quarter. Rafferty Asset Management LLC now owns 411,904 shares of the biopharmaceutical company’s stock valued at $8,477,000 after buying an additional 273,257 shares in the last quarter. 99.22% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. Needham & Company LLC restated a “hold” rating on shares of Sage Therapeutics in a research note on Thursday, April 18th. Morgan Stanley raised their target price on Sage Therapeutics from $20.00 to $22.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 28th. Wedbush restated a “neutral” rating and issued a $24.00 target price on shares of Sage Therapeutics in a research note on Wednesday, April 17th. StockNews.com lowered Sage Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, April 19th. Finally, JPMorgan Chase & Co. raised their target price on Sage Therapeutics from $24.00 to $29.00 and gave the company an “overweight” rating in a research note on Tuesday, March 26th. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, Sage Therapeutics presently has an average rating of “Hold” and a consensus target price of $39.28.

Sage Therapeutics Trading Up 8.1 %

Shares of SAGE opened at $14.00 on Thursday. Sage Therapeutics, Inc. has a 1 year low of $10.92 and a 1 year high of $59.99. The stock has a market cap of $841.50 million, a P/E ratio of -1.55 and a beta of 0.86. The stock’s 50-day moving average price is $18.99 and its two-hundred day moving average price is $20.73.

Sage Therapeutics (NASDAQ:SAGE) last issued its earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.28) by $0.73. Sage Therapeutics had a negative return on equity of 54.41% and a negative net margin of 626.32%. The firm had revenue of $77.97 million for the quarter, compared to analysts’ expectations of $60.15 million. During the same quarter last year, the business earned ($2.47) earnings per share. The company’s revenue was up 2621.5% compared to the same quarter last year. As a group, equities analysts forecast that Sage Therapeutics, Inc. will post -6.3 EPS for the current year.

Sage Therapeutics Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.